What Spencer Trask & Co does

Spencer Trask & Co. is a privately held advanced technology development firm headquartered in Greenwich, Connecticut, that operates as both a venture creator and early-stage investor. The modern firm was re-established under Chairman Kevin Kimberlin and traces its institutional lineage to the original Spencer Trask, who financed Thomas Edison, founded the world's first electric power company, purchased The New York Times in 1896, and underwrote the Marconi Wireless Telegraph Company and Moody's statistical services. Under its contemporary identity, Spencer Trask co-founds or first-funds transformative technology companies at the conception phase and provides capital, strategic guidance, and operational support through to exit. Its portfolio spans healthcare and biotech (Myriad Genetics, Immune Response Corporation with Jonas Salk, Osiris Therapeutics, Health Dialog, Vesselon, Good Measures), technology infrastructure (Ciena, DFMsim now in Applied Materials' AiX platform), legal technology (Fastcase, merged into vLex), supply chain AI (Interos.ai), and financial technology (SeedInvest, which merged into Circle/USDC). The firm states that it co-founded or first-funded twelve startups that each reached valuations exceeding $1 billion, that its portfolio companies have raised more than $5 billion from strategic and institutional partners, and that those companies have created over 100,000 jobs.

Economically, Spencer Trask generates revenue through portfolio exit proceeds (capital appreciation from acquisitions and IPOs) and strategic advisory and development services for its portfolio companies. The firm does not publicly disclose pricing, fund size, AUM, or revenue; its management team is small (11-50 employees) and concentrated, led by Chairman Kevin Kimberlin, CEO emeritus William Clifford (formerly CEO of Gartner Group), Managing Directors Paul Latchford and Neil Edwards, Chief of Staff Kerry Safir, Chief Communications Officer Jamie Dunne, and Chief Technology Officer Ron Buesing. Notable recent exits include Health Dialog (acquired for $775 million by BUPA), the vLex-Fastcase combination (acquired by Clio for $1 billion in July 2025), Good Measures (acquired by NationsBenefits in November 2024), and Circle Internet Financial (NYSE IPO in June 2025 following USDC's $25 trillion+ in on-chain transactions). The firm's stated philosophy centers on a "double bottom line" — pursuing both net worth (financial return) and net worthiness (societal impact) — and it cultivates a network of more than 38 strategic, institutional, and corporate partners including BlackRock, Fidelity, Bain Capital, Kleiner Perkins, Venrock, Goldman Sachs, Accenture, and major pharmaceutical companies.

Name

Spencer Trask & Co

Legal name

Spencer Trask & Co.

Website

https://spencertraskco.com

Company type

Private

Founded year

1860

Operating status

Operating

Headcount range

11–50 employees

Short description

Spencer Trask & Co. is a privately held Greenwich, Connecticut-based advanced technology development firm that co-founds and first-funds transformative ventures in healthcare, AI, semiconductors, legal technology, and financial technology from conception through exit. The firm has produced 12 unicorns, $5B+ in portfolio capital raised, and recent exits including Clio's $1B vLex-Fastcase acquisition and Circle's 2025 NYSE IPO.

Ownership category

akta.pro rank

Headquarters

HQ city

Greenwich

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Investment Returns / Portfolio Exit Revenue: The firm generates returns through successful exits of portfolio companies. Examples include Health Dialog ($770M acquisition), Fastcase-vLex ($1B acquisition by Clio), SeedInvest (acquired by Circle which went public), and various other venture investments. The firm's revenue is derived from capital appreciation and exit proceeds from transformative technology companies they help build.
2. Strategic Advisory and Development Services: The firm provides advanced technology development services, helping entrepreneurs transform concepts into world-leading ventures. This includes strategic guidance, operational support, and access to their network of investors and partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Spencer Trask & Co. is an advanced technology development firm that discovers bright ideas and helps brilliant entrepreneurs turn them into world-changing ventures. The firm provides capital, strategic guidance, and operational support during the conception phase, focusing on transformative companies across healthcare/biotech, AI, genomics, telecommunications, semiconductor, legal technology, and digital currency sectors.

Product overview

Spencer Trask & Co. is an advanced technology development firm that discovers and builds transformative technology ventures. Rather than a single product, they operate a portfolio of technology companies across multiple sectors: healthcare (Good Measures, Health Dialog, Immune Response, Osiris Therapeutics, Myriad Genetics, Vesselon), technology infrastructure (Ciena, DFMsim/AiX, Interos.ai), legal technology (Fastcase/vLex), and financial technology (SeedInvest, Circle/USDC). The firm takes a hands-on approach, providing leadership, capital, and strategic guidance from venture conception through exit. Their portfolio has generated 12 unicorns ($1B+ valuations) and received over $5 billion in investments. The companies work across AI-powered platforms for personalized nutrition, legal research, supply chain monitoring, genomics, stem cell therapy, drug delivery, and digital currency.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital Investment Provides capital investment in transformative technology ventures during the conception and growth phases, targeting startups across healthcare, AI, telecommunications, legal technology, and digital currency.
• Strategic Advisory Services Provides strategic guidance, operational support, and access to a network of strategic, institutional, and corporate investors to entrepreneurs during the fragile conception phase of venture development.
• Venture Development Services Hands-on venture development and incubation services that transform concepts into tangible products, services, and world-leading ventures, applying a 'double bottom line' approach of Net Worth and Net Worthiness.

Quantifiable outcome

• 12 startups each grew to valuations exceeding $1 billion
• +4 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability12 records

Partnerships

Five partnerships are on record, tiered major.

• NationsBenefitsmajorStrategic or Co-development PartnerNationsBenefits acquired Spencer Trask venture Good Measures in November 2024. NationsBenefits serves over 100 health plans and delivers 25 million meals annually, creating the first nationally scaled Food as Medicine platform.
• Circle Internet FinancialmajorStrategic or Co-development PartnerSeedInvest (Spencer Trask portfolio) merged into Circle at USDC launch. Circle conducted IPO in June 2025. Spencer Trask is first investor in Circle/USDC stablecoin.
• CliomajorStrategic or Co-development PartnerClio acquired vLex-Fastcase (Spencer Trask portfolio company) for $1 billion in June 2025. Clio is the leading cloud practice-management platform used by more than 200,000 law firms.
• vLexmajorStrategic or Co-development PartnervLex merged with Spencer Trask portfolio company Fastcase in 2023, creating the world's largest AI-enabled legal research platform serving 3.8 million users across 100+ countries.
• InterosmajorStrategic or Co-development PartnerInteros acquired Spencer Trask's AI platform (Trensant AI) and reached unicorn status with $300M+ raised from Accenture, Venrock, Knight Dragon, Kleiner Perkins, Coupa, Blue Owl, and others. Interos tracks 350 million entities and 18 billion business relationships.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Flagship Pioneering: Venture creation firm that originates and builds biotech and platform companies from novel scientific concepts, mirroring Spencer Trask's conception-phase model of co-founding transformative ventures in healthcare and life sciences.
• ARCH Venture Partners: Early-stage venture firm focused on founding and seeding breakthrough science and technology companies, comparable to Spencer Trask's model of backing first-in-category companies in biotech, AI, and deep tech.
• Lux Capital: Frontier-technology venture firm investing at the intersection of science, technology, and innovation, closely aligned with Spencer Trask's portfolio mix of AI infrastructure, semiconductors, and life sciences.
• Khosla Ventures: Early-stage venture firm with a high-conviction, founder-first approach to technology, healthcare, and sustainability, comparable to Spencer Trask's willingness to back transformative, science-led companies at the idea stage.
• Founders Fund: Early-stage venture firm investing in transformative technologies across healthcare, fintech, and frontier tech, with a similar thesis of backing bold, world-changing companies at the conception phase.

Broad incumbents

• Andreessen Horowitz (a16z): Large-scale venture firm with broad sector coverage across bio/health, AI, fintech, and crypto, overlapping with several of Spencer Trask's portfolio themes (USDC/stablecoins, legal tech, healthcare) but with much greater scale and resources.
• Kleiner Perkins: Historic venture firm investing across technology, healthcare, and consumer, including a co-investment relationship with Spencer Trask portfolio company Interos; comparable in cross-sector transformative-tech focus.
• Venrock: Long-tenured venture firm with deep technology and healthcare roots that has co-invested with Spencer Trask in Interos, sharing a thesis of early identification of category-defining technology companies.
• General Catalyst: Global venture firm with strong healthcare and technology franchises, comparable to Spencer Trask's emphasis on transformative science and technology investments at the earliest stages.

Others

• In-Q-Tel: Strategic not-for-profit investor that identifies and funds early-stage technologies with national-security and mission impact, thematically similar to Spencer Trask's emphasis on transformative, mission-driven technology bets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SpencerTrask
• LinkedInlinkedin.com/company/33539

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments15 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spencer Trask & Co